“𝗜𝗻𝘀𝗮𝗻𝗶𝘁𝘆 𝗶𝘀 𝗱𝗼𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝘁𝗵𝗶𝗻𝗴 𝗼𝘃𝗲𝗿 𝗮𝗻𝗱 𝗼𝘃𝗲𝗿 𝗮𝗴𝗮𝗶𝗻 𝗮𝗻𝗱 𝗲𝘅𝗽𝗲𝗰𝘁𝗶𝗻𝗴 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗿𝗲𝘀𝘂𝗹𝘁𝘀.” 𝗙𝗼𝗿 𝗱𝗲𝗰𝗮𝗱𝗲𝘀, 𝘁𝗵𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗵𝗮𝘀 𝗽𝗼𝘂𝗿𝗲𝗱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻𝘀 𝗶𝗻𝘁𝗼 𝗮 𝘀𝗶𝗻𝗴𝘂𝗹𝗮𝗿 𝗴𝗼𝗮𝗹 𝗳𝗼𝗿 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲: 𝗰𝗹𝗲𝗮𝗿𝗶𝗻𝗴 𝗮𝗺𝘆𝗹𝗼𝗶𝗱 𝗽𝗹𝗮𝗾𝘂𝗲𝘀 𝗮𝗻𝗱 𝘁𝗮𝘂 𝘁𝗮𝗻𝗴𝗹𝗲𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗯𝗿𝗮𝗶𝗻. 𝗬𝗲𝘁, 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗮𝗳𝘁𝗲𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗵𝗮𝘀 𝗳𝗮𝗰𝗲𝗱 𝗱𝗶𝘀𝗮𝗽𝗽𝗼𝗶𝗻𝘁𝗶𝗻𝗴 𝗳𝗮𝗶𝗹𝘂𝗿𝗲𝘀. 𝗧𝗵𝗲 𝗽𝗹𝗮𝗾𝘂𝗲𝘀 𝗮𝗿𝗲 𝗿𝗲𝗺𝗼𝘃𝗲𝗱, 𝗯𝘂𝘁 𝘁𝗵𝗲 𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝘃𝗲 𝗱𝗲𝗰𝗹𝗶𝗻𝗲 𝗽𝗲𝗿𝘀𝗶𝘀𝘁𝘀.

𝗪𝗵𝘆 𝘁𝗵𝗲 𝗺𝗮𝘀𝘀𝗶𝘃𝗲 𝗱𝗶𝘀𝗰𝗼𝗻𝗻𝗲𝗰𝘁?

In my latest paper published this week in Free Neuropathology (June 2026), I propose a fundamental shift in how we view this disease: The Dual Sequestration Hypothesis (DSH).

What if these plaques and tangles aren’t the actual cause of the disease, but are instead the brain’s natural “defense structures” trying to trap an entirely different, hidden enemy?

In the modern “Plasticene” era, micro- and nanoplastics are entering our environments—and our bodies. Our research suggests these indestructible particles act as permanent seeds that hijack the brain’s immune system, creating a state of chronic “immune frustration.”

When we develop therapies that destroy the brain’s defense structures without removing the toxic plastic core underneath, we leave the true trigger behind. This explains both the therapeutic failures and common trial side effects like ARIA.

Solving the world’s toughest healthcare challenges requires stepping outside the consensus and looking at the intersection of environmental toxicology and classic pathology.

Read the full, open-access paper here: https://ejournals.uni-muenster.de/fnp/article/view/9368/9665

Journal: Free Neuropathol. 2026 Jun 22;7:14.
DOI: 10.17879/freeneuropathology-2026-9368.
PMID: 42344202.
#Biotech #HealthcareInnovation #AlzheimersResearch #ExecutiveLeadership #Pharmaceuticals #PublicHealth